Cardiac Fibrosis Clinical Trial
Official title:
Immune Correlates of Cardiac Structure and Function
Verified date | October 2022 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to determine the occurrence of scarring of the heart (cardiac fibrosis) and inflammation in those with perinatally acquired Human Immunodeficiency Virus (HIV) infection compared to people not infected with HIV. The information learned from this research may help the investigator to better understand the link between cardiac fibrosis and cardiac dysfunction and inflammation in those with perinatally acquired HIV infection compared to the uninfected. Participants will have a blood sample, complete a patient questionnaire, and have a Magnetic resonance imaging (MRI) and ultrasound of the heart. Researchers will review the medical record and past medical history, for information about your heart function and overall health. Research samples and data from this study will be stored indefinitely and used for other research. There are risks to participate in this study and those risks include side effects from the contrast agent used for the MRI scan, (such as headache and injection site pain), and risks from blood sampling.
Status | Completed |
Enrollment | 40 |
Est. completion date | September 21, 2022 |
Est. primary completion date | September 21, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 45 Years |
Eligibility | Inclusion Criteria: 1. Individuals 20-45 years of age 2. Willingness and ability to provide signed and dated written informed consent, prior to any study-related procedures 3. Diagnosed with HIV <10 years of age or physician confirmation of perinatal HIV infection 4. On antiretroviral treatment (ART) for at least the last greater than or equal to 6 months 5. Willingness to undergo Cardiovascular magnetic resonance imaging (CMR) 6. Willingness to undergo echocardiogram (ECHO) (may be included if ECHO has been done at Duke in the previous 24 months). 7. Willingness to have research blood draw Exclusion Criteria: 1. Contraindication to CMR (metal fragments in eyes or face, implanted electronic devices such as pacemakers, defibrillators, cochlear implants, or nerve stimulators, aneurysm clips) 2. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2 3. History of anaphylactic reaction to gadolinium contrast 4. Inability to complete an MRI scan in the past due to anxiety 5. Recent acute medical illness resulting in recent hospitalization (in past 90 days) 6. History of: Coronary artery disease (CAD), Myocardial infarction (MI), moderate-severe valvular disease, congenital heart disease, heart failure, non-ischemic CM, Atrial fibrillation/flutter, implantable cardioverter defibrillator (ICD)/pacemaker, myocarditis prior 7. Current Symptoms of Shortness of breath, severe chest pain, palpations, difficulty breathing on exertion, swelling of legs 8. Known to be pregnant or current breastfeeding 9. Known to be on hemodialysis 10. Inability to breath hold for 5-10 seconds 11. Known to have an ejection fraction <45% in the past 24 months 12. Active cancer or cancer chemotherapy or radiation treatment in the prior year. 13. Comorbid inflammatory disease, specifically treated for rheumatoid arthritis (RA) or lupus (SLE) 14. Chronic use of steroids or anti-inflammatory therapy |
Country | Name | City | State |
---|---|---|---|
United States | Duke University Health System | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Williams JL, Hung F, Jenista E, Barker P, Chakraborty H, Kim R, McCrary AW, Shah SH, Thielman N, Bloomfield GS. Diffuse myocardial fibrosis is uncommon in people with perinatally acquired human immunodeficiency virus infection. AIDS Res Ther. 2024 Mar 4;21(1):13. doi: 10.1186/s12981-024-00598-4. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Myocardial fibrosis by cardiac magnetic resonance (CMR) imaging | Compare myocardial fibrosis for HIV+ and control subjects (unit = percentage) | Baseline Visit | |
Secondary | Cardiac function evaluated using cine cardiac magnetic resonance imaging | Compare Left ventricular ejection fraction (LVEF) for HIV+ and control subjects (unit = percentage) Compare left ventricle (LV) mass for HIV+ and control subjects (unit = grams) | Baseline Visit | |
Secondary | Myocardial edema evaluated using native T2 mapping cardiac magnetic resonance imaging | Compare native T2 mapping values for HIV+ and control subjects (unit = ms) | Baseline Visit | |
Secondary | Diffuse fibrosis evaluated using native T1 mapping cardiac magnetic resonance imaging | Compare native T1 mapping values for HIV+ and control subjects (unit = ms) | Baseline Visit | |
Secondary | Extra-cellular volume (ECV) cardiac magnetic resonance imaging | Compare ECV for HIV+ and control subjects (unit=percentage) | Baseline Visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04177251 -
Cardiovascular Fibrosis in Idiopathic Pulmonary Fibrosis
|
||
Active, not recruiting |
NCT05317806 -
Metformin Use in Cardiac Fibrosis in PAI-1 Deficiency
|
Phase 4 | |
Terminated |
NCT00952627 -
Effects of Pycnogenol on Cardiac Fibrosis and Diastolic Dysfunction in Aged Hypertensive Subjects
|
Phase 2 | |
Active, not recruiting |
NCT02921321 -
Pilot Study of Cardiac MR in Patients With Muscular Dystrophy
|
||
Completed |
NCT03509441 -
Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance
|
||
Completed |
NCT03391128 -
Circulating P3NP and Cardiovascular Events in Hemodialysis Patients
|
N/A | |
Recruiting |
NCT03197350 -
Characterization of Heart Failure With Preserved Ejection Fraction
|
N/A | |
Recruiting |
NCT05689710 -
The Effects of Inositol on Glucose Metabolism in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis
|
N/A |